Where Will Amgen Be in 5 Years?

Amgen (NASDAQ: AMGN) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S 500's 90% gain over that stretch. With some promising products in its pipeline, the future does looks encouraging. However, some investors might be concerned about the company's high debt load.

Here's where the business might go from here, and whether it's worth investing in Amgen today.

The biggest product Amgen investors should be excited about is MariTide, a weight loss drug that could prove to be a thorn in the sides of both Novo Nordisk and Eli Lilly.

Source Fool.com

Amgen Inc. Aktie

Amgen Inc. muss heute leichte Verluste wegstecken. Die Aktie notiert im Vergleich zu gestern um -0,57 % tiefer.
Die Community bevorzugt Amgen Inc., mit deutlich mehr Buy- (42) als Sell-Einschätzungen (4).
Trotz eines Kursziels von 340 € für Amgen Inc., das unter 356.9 € liegt, zeigt sich ein Potenzial von -4.74%.

Like: 0

AMGN

Teilen